Not surprisingly, we also demonstrated that clinical features such as age, tumor size, nodal status, Ki-67 level, and comorbidity influenced chemotherapy regimen choice in the basis of trastuzumab treatment. This evidence concerns the gene MKI67 and neoplasm.